**DRUG NAME:** Etoposide phosphate

**SYNONYM(S):** Refer to etoposide monograph

**COMMON TRADE NAME:** ETOPOPHOS®

**CLASSIFICATION:** Refer to etoposide monograph

**MECHANISM OF ACTION:**
Refer to etoposide monograph

**PHARMACOKINETICS:**
Refer to etoposide monograph

**USES:**
Refer to etoposide monograph

**SPECIAL PRECAUTIONS:**
Refer to etoposide monograph
- etoposide phosphate is NOT interchangeable with other etoposide formulations and should not be substituted

**SIDE EFFECTS:**
Refer to etoposide monograph

Allergic reactions may be less common and severe than etoposide because etoposide phosphate does not contain polysorbate 80. Etoposide phosphate has been safely administered in patients with previous hypersensitivity, although rare cross-sensitivity has been reported.

**INTERACTIONS:**
Refer to etoposide monograph

**SUPPLY AND STORAGE:**

*Injection:* Etoposide phosphate (ETOPOPHOS®) is not commercially available in Canada. It is supplied as a 100 mg single dose vial. Refrigerate. Keep in original packaging and protect from light.

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

**SOLUTION PREPARATION AND COMPATIBILITY:**

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Additional information:
- Etoposide phosphate is a water soluble ester of etoposide which lessens the potential for precipitation following dilution and intravenous administration.
- Etoposide phosphate does not contain polysorbate 80. Therefore, diethylhexyl phthalate (DEHP) does not leach from polyvinyl chloride (PVC) containers and tubing into etoposide phosphate IV solution. Etoposide phosphate does not require non-DEHP containers and tubing for administration.
PARENTERAL ADMINISTRATION:
Refer to etoposide monograph

<table>
<thead>
<tr>
<th>Direct intravenous</th>
<th>not to be administered by direct IV route(^1)</th>
</tr>
</thead>
</table>
| Intermittent infusion | • dilute to final concentration of 0.1 mg/mL or greater\(^1\)  
                         • over 5 minutes to 3.5 hours\(^1\) (e.g., over 30 minutes)\(^5\)  
                         • non-DEHP administration sets not required |

DOSAGE GUIDELINES:
Refer to etoposide monograph

REFERENCES: